



Bwrdd Iechyd
Addysgu Powys
Powys Teaching
Health Board

Information Governance Team
Hafren Ward
Bronllys Hospital
Bronllys
Brecon
Powys LD3 0LY
Email: Powys.FOI@wales.nhs.uk
Tel: 01686 252159/01874 442071

Our ref: IG/FOI/24.R.100

12 March 2024

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 26 February 2024, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does hold the information that you require.

Your Freedom of Information (FOI) Request:

Please could you provide me with the information relating to my questions below:

Q1. Please can you provide the name and email address of the medicines management team member who led on the Eye Care (Chapter 11) formulary review when it was last reviewed?

Q2. Please can you provide the name and email address of the member of the Health Board Medicines management team who is currently responsible for overseeing Eye Care formularies?

Q3. Do you have an area prescribing committee/Medicines Optimisation Committees/ Medicines advisory group or similarly named group that manages your drug formulary decisions?

Q4. Please can you provide the names and email addresses of all members of these formulary groups?

Q5. Please can you provide copies of the previous two minutes from the Area Prescribing Committee/ Medicines Optimisation Committees/ Medicines advisory group or similarly named groups meetings?

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661



Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661

Rydym yn croesawu gohebiaeth Gymraeg
Bwrdd Iechyd Addysgu Powys yw enw gweithreidd Bwrdd Iechyd Lleol
Addysgu Powys



We welcome correspondence in Welsh
Powys Teaching Health Board is the operational name of
Powys Teaching Local Health Board

Q6. I would be grateful if you could confirm for which products within Chapter 11 (Eye) of your formulary, you have a primary care rebate in place, when the agreement commenced, the rebate amount and the end date?

Q7. Does the Health Board have a deficit forecast for 2023/2024 financial year? If so, how much is this deficit? And how much is the forecast deficit for 2024/2025 financial year?

Q8. What is the value of your Health Boards's planned savings from the Medicines management drug prescribing budget in the financial year: 2023-2024? And 2024 – 2025?

Powys Response:

Q1 I can confirm the review was undertaken by members of the Formulary Working Group (FWG), with specialist input from the health board's Optometry Adviser during October 2023. The FWG terms of reference are attached detailing the membership - Attachment 1. Members can be contacted via info.medicinesmanagement.powys@wales.nhs.uk

Q2 Responsibility sits with the FWG with specialist input from the health board's Optometry Adviser.

Q3 Responsibility sits with the FWG who makes recommendations to the Area Prescribing Group.

Q4 Terms of reference of FWG and Area Prescribing Group (APG) please see FOI 24.R.100 Attachment 2. Members can be contacted via info.medicinesmanagement.powys@wales.nhs.uk

Q5 Please find attached minutes for the APG:

- FOI 24.R.100 Attachment 3 APG Minutes June 2023
- FOI 24.R.100 Attachment 4 APG Minutes September 2023

Please notes December's minutes are still in draft, so cannot be provided.

Q6 The following products are in chapter 11 of the PTHB formulary and are subject to a primary care rebate.

	Start date	End date
Evolve Hypromellose	Jan-20	Jun-24
Xailin Plus	Jul-22	Jun-24

The exact details of each individual rebate scheme are commercially sensitive therefore we are withholding this information under Section 43 Commercial Interests of the Freedom of Information Act. This section of the Act sets out an exemption from the right to know if releasing the information is likely to prejudice the commercial interests of any person (a person maybe an individual, company, the public authority itself or any other legal entity).

This exemption was considered by the Health Board when deciding whether to release this information because it was felt that, in doing so, it could create a

significant risk in prejudicing the commercial interests of the companies involved and the Health Board.

As this is a qualified exemption the Health Board must consider the public interest in deciding whether to withhold or disclose the information. The Health Board accepts that there is a public interest in ensuring openness and transparency. However, the Health Board believes that disclosure of information in a manner which fails to protect the interests and relationships arising in a commercial context could discourage third parties from dealing with the Health Board because of fears that the disclosure of information could damage them commercially. In turn, this could jeopardise the Health Board's ability to compete fairly and pursue its function to bring forward development in the area and obtain value for money. As a result, exemption section 43 is engaged as it is not considered in the public interest to disclose this information.

Q7 PTHB does have a deficit forecast for 2023/2024 financial year of £1,037K. PTHB are working towards a breakeven position for 2024/2025 financial year.

Q8 The value of PTHB's planned savings from the Medicines management drug prescribing budget in the financial year: 2023-2024 is £506K. Figures for 2024 – 2025 are currently being confirmed.

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via powysfoi.foi@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



Kate Wright
Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay